Phase 3 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a written consent form before any trial-related procedures take place.
• People aged 18 or older.
• People with cancer that has spread to other parts of the body (or is locally advanced and not suitable for local treatment), where the cancer type has been confirmed by a tissue test, including: lung cancer, kidney cancer, head and neck cancer, bladder/urinary tract cancer, triple negative breast cancer, Merkel cell cancer, liver cancer, melanoma, bowel cancer with a specific genetic marker (MSI), oesophageal squamous cell cancer, uterine cancer, cervical cancer, stomach or stomach-oesophagus junction cancer, basal cell skin cancer, or squamous cell skin cancer.
• People whose cancer has partially or completely responded to standard immunotherapy after at least 6 months of treatment, as confirmed by scans.
• People with metastatic melanoma who have had a partial response to immunotherapy (note: complete responders with melanoma are not eligible — confirm with trial site).
• People whose treating doctor considers them suitable to continue on the same immunotherapy treatment.
• People who are relatively well and active, with a fitness score of 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity).
• People with brain metastases that have been treated (with surgery or targeted radiation) and have been stable, with no signs of new or growing brain tumours before entering the trial.
• People who previously received immunotherapy combined with chemotherapy, targeted therapy (TKI), pemetrexed, or bevacizumab.
• Women who have gone through menopause, or women of childbearing age who have a negative pregnancy test.
• People who agree to use adequate contraception during and after the study treatment, as directed by the treatment guidelines.
• People who are willing and able to attend all required visits, treatments, and follow-up appointments for the full duration of the trial.
• People who are enrolled in a national social security or health insurance system (this criterion is specific to the French healthcare system — confirm with trial site).

Who may not be able to join:

• People with metastatic melanoma whose cancer has completely disappeared in response to immunotherapy.
• People with metastatic kidney cancer classified as "favourable risk" (by a specific medical scoring system) who are being treated with a combination of targeted therapy and immunotherapy.
• People with blood cancers such as leukaemia, myeloma, or lymphoma.
• People with an active infection that requires systemic (whole-body) treatment, such as antibiotics given by mouth or through a drip.
• People who are currently enrolled in another treatment-based clinical trial, or who have been in one within the 30 days before joining this trial.
• People who are unable to follow the study requirements due to geographic, personal, social, or physical reasons, or who are unable to understand the study's purpose and procedures.
• People who are in legal custody, under guardianship, or otherwise deprived of their liberty.

Important: Always verify eligibility with the trial site directly before applying.